Pharming Financial Statements From 2010 to 2025
| PHGUF Stock | USD 0.90 0.11 13.92% |
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as , as well as many indicators such as . Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
Pharming |
Pharming Group NV Company Return On Equity Analysis
Pharming Group's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Pharming Group Return On Equity | 0.17 |
Most of Pharming Group's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharming Group NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Pharming Group NV has a Return On Equity of 0.1669. This is 100.7% lower than that of the Healthcare sector and 100.46% lower than that of the Biotechnology industry. The return on equity for all United States stocks is 153.84% lower than that of the firm.
Pharming Group NV Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharming Group's current stock value. Our valuation model uses many indicators to compare Pharming Group value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharming Group competition to find correlations between indicators driving Pharming Group's intrinsic value. More Info.Pharming Group NV is regarded second in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers reporting about 0.39 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Pharming Group NV is roughly 2.60 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharming Group's earnings, one of the primary drivers of an investment's value.About Pharming Group Financial Statements
Pharming Group stakeholders use historical fundamental indicators, such as Pharming Group's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in Pharming Group's assets and liabilities are reflected in the revenues and expenses on Pharming Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Pharming Group NV. Please read more on our technical analysis and fundamental analysis pages.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Grp operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 277 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pharming Pink Sheet
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's future performance. For an informed investment choice regarding Pharming Pink Sheet, refer to the following important reports:Check out the analysis of Pharming Group Correlation against competitors. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.